Royalty Pharma Plc Cl A (RPRX) Stock Price, Quote & News

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Industry: Biotechnology

Sector: Healthcare

Phone: 212 883 0200

Website: www.royaltypharma.com

Address:

110 East 59th Street, New York, United States

ZacksResearch Jan. 12 at 4:50 PM

$TEVA and $RPRX team up for a promising vitiligo treatment! Teva’s latest $500M funding agreement with Royalty Pharma boosts its TEV-’408 development, targeting a massive unmet need in the autoimmune space. Early phase Ib data offers initial validation of IL-15 as a promising therapeutic target for diseases like vitiligo. Find out how this strategic move could reshape TEVA's future 👉 https://www.zacks.com/stock/news/2815809/teva-signs-deal-with-rprx-to-accelerate-development-of-vitiligo-drug?cid=sm-stocktwits-2-2815809-body-28451&ADID=SYND_STOCKTWITS_TWEET_2_2815809_BODY_28451

0 · Reply

ZacksResearch Jan. 12 at 3:50 PM

$TEVA lands a big funding win — vitiligo drug push just sped up Teva signed a $500M funding deal with $RPRX to accelerate development of its vitiligo candidate, TEV-'408, while retaining global commercial control — a notable balance of capital and control. Get the full breakdown on what this deal means for TEVA 👉 https://www.zacks.com/stock/news/2815809/teva-signs-deal-with-rprx-to-accelerate-development-of-vitiligo-drug?cid=sm-stocktwits-2-2815809-teaser-28434&ADID=SYND_STOCKTWITS_TWEET_2_2815809_TEASER_28434

0 · Reply

StocktwitsNews Jan. 12 at 1:53 PM

Why Is TEVA Stock Rising Pre-Market Today? $TEVA $RPRX https://stocktwits.com/news/equity/markets/why-is-teva-stock-rising-pre-market-today/cmUaGqaR4EB

0 · Reply

Quantumup Jan. 12 at 11:29 AM

Leerink reit'd $ANAB OP/$64 after $RPRX & $TEVA announced a funding agreement of up to $500 million to accelerate devt of TEV-53408, TEVA's IL-15 monoclonal antibody. We view this transaction as incrementally positive for ANAB, as it further validates the IL-15/CD122 axis and should benefit investor perception of this therapeutic class, including ANB033. Under the agreement, RPRX will provide $75 million to fund a Ph2b program, with an option to invest an additional $425 million to support later-stage development. Recall TEVA is advancing TEV-53408 in two ongoing studies: a Ph2 trial in celiac disease (CeD, N=48, est. PC Sep 2026, NCT06807463) and a Ph1 trial in vitiligo (N=36, est. PC May 2026, NCT06625177). TEV-53408 is designed with a 38-day half-life and is intended for quarterly or less frequent dosing. TEVA anticipates sharing results from TEV-53408 trials during 2026. ANB033 is a CD122 antagonist which inhibits both the IL15 and IL2 signaling pathways. Maintain OP on ANAB shares.

0 · Reply

carlwilliambrown Jan. 12 at 10:17 AM

$RPRX $TEVA

0 · Reply

AlertsAndNews Jan. 11 at 10:56 PM

$RPRX $TEVA Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo "Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-‘408 "

0 · Reply

TechridyStocks Jan. 7 at 5:06 PM

$RPRX bullish over $41.01

0 · Reply

Night_Owl_Biotech Dec. 31 at 4:01 PM

Since 1/1/13 we're unaware of any synergistic value opportunity that appears to exist between $INCY & $SNDX The opportunity appears so massive it could almost be a disservice to INCY shareholders to not buy SNDX (again could be). See the attached FY29/FY30 revenue multiples, after Jakafi patent exp INCY has an existing portfolio of 3 FDA approved hematology focused therapies, incl Niktimvo. There's virtually no incremental costs to INCY to add SNDX's Revuforj to their global comm'l & distribution systems. See our previous post where we calculated the NPV of the amounts due from INCY to SNDX to be just under $2B (using a 14% discount rate & $RPRX published Niktimvo revenue estimates thru FY38) INCY had ~$3B cash @ 9/30/25. INCY expects to earn interest @ 4% at best. INCY's $3B cash is 1.6X SNDX's market cap @ $21/share. Again our NPV calc used a 14% rate of return INCY's CEO was on SNDX's BOD through June 2025 Of course we could also be wrong about INCY/SNDX This is not investment advice

1 · Reply

notreload_ai Dec. 29 at 10:11 PM

$RPRX acquires complete royalty interest in Roche's Evrysdi for $240M upfront plus milestones, consolidating ownership of the 8-16% tiered royalty stream. https://notreload.xyz/royalty-pharma-completes-240m-deal-for-full-evrysdi-royalty-rights/

0 · Reply

dixiebull Dec. 26 at 11:13 AM

$VNDA getting attention like OMER did before the halt also watching $RPRX

0 · Reply

Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 12:26 PM EST - 1 day ago

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

TEVA

Jan 12, 2026, 7:15 AM EST - 1 day ago

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 5:15 PM EST - 2 days ago

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 9, 2026, 8:30 AM EST - 4 days ago

Royalty Pharma Announces Dividend Increase

Dec 29, 2025, 4:40 PM EST - 15 days ago

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Dec 16, 2025, 7:15 AM EST - 4 weeks ago

Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million

Dec 4, 2025, 7:10 AM EST - 5 weeks ago

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:00 AM EST - 5 weeks ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

DNLI

Dec 3, 2025, 6:13 PM EST - 5 weeks ago

Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 5:33 PM EST - 6 weeks ago

Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 26, 2025, 8:15 AM EST - 6 weeks ago

Royalty Pharma to Present at Upcoming Investor Conferences

Nov 15, 2025, 7:12 AM EST - 2 months ago

Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated

Nov 5, 2025, 1:01 PM EST - 2 months ago

Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:00 AM EST - 2 months ago

Royalty Pharma Reports Third Quarter 2025 Results

Nov 4, 2025, 7:15 AM EST - 2 months ago

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

Oct 17, 2025, 8:15 AM EDT - 3 months ago

Royalty Pharma Declares Fourth Quarter 2025 Dividend

Oct 9, 2025, 4:15 PM EDT - 3 months ago

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

Sep 29, 2025, 8:15 AM EDT - 3 months ago

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Sep 23, 2025, 5:23 PM EDT - 4 months ago

Royalty Pharma plc (RPRX) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Sep 19, 2025, 4:25 PM EDT - 4 months ago

Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum

Sep 12, 2025, 3:54 PM EDT - 4 months ago

Royalty Pharma: Investor Day Upside

Sep 11, 2025, 8:16 PM EDT - 4 months ago

Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)

Sep 11, 2025, 7:00 AM EDT - 4 months ago

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

Sep 10, 2025, 7:30 AM EDT - 4 months ago

Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market

Sep 9, 2025, 6:07 PM EDT - 4 months ago

Royalty Pharma Plc (RPRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 4:15 PM EDT - 4 months ago

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:30 PM EDT - 4 months ago

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

Sep 2, 2025, 7:15 AM EDT - 4 months ago

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Sep 2, 2025, 7:05 AM EDT - 4 months ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

ZBIO

Aug 25, 2025, 6:33 AM EDT - 5 months ago

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

AMGN

Aug 25, 2025, 6:10 AM EDT - 5 months ago

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

Aug 25, 2025, 6:00 AM EDT - 5 months ago

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

ONC

Aug 13, 2025, 4:15 PM EDT - 5 months ago

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

Aug 9, 2025, 6:23 AM EDT - 5 months ago

Royalty Pharma: Keep Delivering, Buy Confirmed

Aug 6, 2025, 3:52 PM EDT - 5 months ago

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 5 months ago

Royalty Pharma Reports Second Quarter 2025 Results

Aug 1, 2025, 8:31 AM EDT - 5 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 5 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 18, 2025, 8:15 AM EDT - 6 months ago

Royalty Pharma Declares Third Quarter 2025 Dividend

Jul 17, 2025, 8:15 AM EDT - 6 months ago

Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors

Jul 16, 2025, 4:15 PM EDT - 6 months ago

Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025

Jul 1, 2025, 5:23 AM EDT - 7 months ago

Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline

Jun 24, 2025, 7:19 AM EDT - 7 months ago

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

RVMD

Jun 24, 2025, 7:05 AM EDT - 7 months ago

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

Jun 4, 2025, 4:15 PM EDT - 7 months ago

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 16, 2025, 4:30 PM EDT - 8 months ago

Royalty Pharma Completes the Acquisition of Its External Manager

May 12, 2025, 4:15 PM EDT - 8 months ago

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

May 11, 2025, 9:18 PM EDT - 8 months ago

Royalty Pharma: Again, Guidance Raised, Buy Confirmed

May 8, 2025, 12:44 PM EDT - 8 months ago

Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript

ZacksResearch Jan. 12 at 4:50 PM

0 · Reply

ZacksResearch Jan. 12 at 3:50 PM

0 · Reply

StocktwitsNews Jan. 12 at 1:53 PM

Why Is TEVA Stock Rising Pre-Market Today? $TEVA $RPRX https://stocktwits.com/news/equity/markets/why-is-teva-stock-rising-pre-market-today/cmUaGqaR4EB

0 · Reply

Quantumup Jan. 12 at 11:29 AM

0 · Reply

carlwilliambrown Jan. 12 at 10:17 AM

$RPRX $TEVA

0 · Reply

AlertsAndNews Jan. 11 at 10:56 PM

0 · Reply

TechridyStocks Jan. 7 at 5:06 PM

$RPRX bullish over $41.01

0 · Reply

Night_Owl_Biotech Dec. 31 at 4:01 PM

1 · Reply

notreload_ai Dec. 29 at 10:11 PM

0 · Reply

dixiebull Dec. 26 at 11:13 AM

$VNDA getting attention like OMER did before the halt also watching $RPRX

0 · Reply

CipherCap Dec. 25 at 11:29 AM

$RPRX A transition phase is underway where operating consistency matters more than rapid expansion. Progress needs to be observable in both leading indicators and reported metrics. Missed checkpoints may compound into higher capital costs. Future re‑rating depends on tightening the gap between narrative and reality.

0 · Reply

Quantumup Dec. 22 at 11:50 AM

Citizens⬆️ $CYTK's PT to $88 from $78, reiterated at Market Outperform, and said, 'FDA Approved MYQORZO w/ a Differentiated Label/REMS' $BMY $EWTX $RPRX Citizens additionally said: On Friday, the FDA approved MYQORZO (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). We increase our probability of approval in oHCM to 100% from 90% in both the U.S. and EU to reflect recent regulatory wins and roll forward our valuation year, which drives our increased price target. In our view, the label and REMS are differentiated from CAMZYOS, with potential to be further differentiated with inclusion of the MAPLE-HCM data. Furthermore, we believe the company is fully prepared and optimally funded to execute on the launch. The approval enables it to draw down an additional $175MM under its Royalty Pharma loan agreement.

0 · Reply

Night_Owl_Biotech Dec. 17 at 11:57 PM

Our model calculating the total NPV (net present value) of the $INCY payments due $SNDX thru FY38 under the 50/50 Niktimvo partnership @ $1.959B if (THESE ARE HUGE IFs); 1. Niktimvo US sales forecast data points cited by $RPRX in their 11/2024 investor deck are credible ($350MM for a 13.8% royalty yields a "low double digits" IRR & full repayment @ 2.35X by FY38). Our forecast's IRR = 11.2% 2. 5-year Niktimvo US sales consensus was up 96% from RPRX's original 11/2024 forecast (#1 above), as RPRX noted in their 9/11/2025 investor deck 3. Net collaboration revenue (INCY payment) due SNDX averages 40% of Niktimvo US sales per #2 above (actual Q325 = ~30%) beginning in FY26 4. INCY’s discount rate = 14% (sec .gov has been spotty but peer acquirer's cost of capital range 11-14%). At 12%, the total NPV = ~$2.2B This exercise does not consider SNDX Niktimvo ex-US value (mid-teen royalty) nor Revuforj Of course we c/b wrong. This is for entertainment purposes & not investment advice Genuine pushback?

3 · Reply

topstockalerts Dec. 16 at 3:00 PM

Royalty Pharma announced the acquisition of royalty rights to two next-generation cancer therapies, neladalkib and zidesamtinib, from an undisclosed third party for up to $315 million. The deal covers a low single-digit pre-existing royalty interest in both drugs, which are tyrosine kinase inhibitors targeting specific forms of non-small cell lung cancer. Neladalkib, aimed at ALK-positive NSCLC, reported positive pivotal results in pretreated patients in November 2025 and is also being studied in an ongoing Phase 3 trial for treatment-naïve patients. Zidesamtinib, designed for ROS1-positive NSCLC, is under FDA review with a target action date of September 18, 2026, and is also being evaluated in an early-stage trial in untreated patients. Analyst consensus projects peak sales of about $3.5 billion for neladalkib and $1.9 billion for zidesamtinib by 2035. $RPRX

0 · Reply

OpenOutcrier Dec. 16 at 1:37 PM

$RPRX (+2.3% pre) Royalty Pharma acquires drug royalty rights for up to $315 million https://ooc.bz/l/87612

0 · Reply

Ichigodoran Dec. 12 at 6:50 PM

Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance $IMRX $ONCY $TNGX $RPRX $MRNA https://finviz.com/news/252943/pancreatic-cancer-survival-gains-accelerate-as-novel-therapies-advance

1 · Reply

JarvisFlow Dec. 11 at 4:29 PM

TD Cowen has adjusted their stance on Royalty Pharma ( $RPRX ), setting the rating to Buy with a target price of 42 → 45.

0 · Reply

Goldenpoint9 Dec. 11 at 1:37 PM

$RPRX

0 · Reply

JFDI Dec. 8 at 2:04 PM

$RPRX how many tight weeks is that?

0 · Reply

JackDarwin Dec. 6 at 10:51 AM

$RPRX Bullish Tweezer Candlestick Pattern

0 · Reply

ZacksResearch Dec. 5 at 6:41 PM

$DNLI surges 5.84% on $275M funding deal with $RPRX! 🚀 💰 Deal centers on tividenofusp alfa, targeting Hunter syndrome 📅 FDA's target action date for tividenofusp alfa's BLA is set for April 5, 2026 Discover the full potential of this agreement 👉 https://www.zacks.com/stock/news/2800334/denali-enters-into-a-275m-funding-deal-with-royalty-pharma?cid=sm-stocktwits-2-2800334-body-23715&ADID=SYND_STOCKTWITS_TWEET_2_2800334_BODY_23715

0 · Reply

topstockalerts Dec. 4 at 8:24 PM

Denali Therapeutics shares rose after announcing a $275 million synthetic royalty financing deal with Royalty Pharma for its Hunter syndrome drug candidate, tividenofusp alfa. The agreement includes a $200 million upfront payment and $75 million tied to European approval by the end of 2029. Royalty Pharma will receive 9.25% royalties on global sales until reaching a return multiple, contingent on accelerated FDA approval. The FDA is reviewing the therapy with a target decision date of April 5, 2026. Denali’s CEO said the deal validates the drug’s potential and supports further development using its TransportVehicle technology to treat cognitive and physical symptoms of Hunter syndrome. $DNLI $RPRX

0 · Reply

Market Cap	23.24B
Revenue (ttm)	2.26B
Net Income (ttm)	858.98M
EPS (ttm)	N/A
PE Ratio	8.89
Forward PE	7.92
Profit Margin	37.95%
Debt to Equity Ratio	0.93

Volume	4,907,300
Avg Vol	4,272,996
Day's Range	N/A - N/A
Shares Out	577.24M
Stochastic %K	61%
Beta	0.43
Analysts	Strong Sell
Price Target	$46.86